Join Us in Revolutionizing Medical Technology
Join Us in Revolutionizing Medical Technology
Longevity Is Key
Our innovations and solutions have a product pipeline to target disease-specific therapeutics.
Liver
Lungs
Heart
Kidney
GI
Our combined Approach
Our Solutions brings in house all required service offerings to take a product from concept to maximal delivery in patient populations.
We have built patented, proprietary technology around lyophilized extracellular vesicles (EVs) from 3D grown organoids to effectively treat organ-specific inflammation resulting in longevity.
Collaboration with Cell2Cure to expand the ability to create geographically specific organoids and EVs.
Using in house clinical research organizations and data management platforms lead by industry leaders, Organoid Solutions can streamline the clinical trial process and lower costs by over 40%.
Market size
Cellular-Derived Technologies
- Cell Therapy market projected to reach $48.11B by 2027 with a 25.6% CAGR.
- Exosome Therapy market anticipated at $32B by 2026, growing at a 21.69% CAGR.
- Expected market capture of 15% in cell-based products using oral technology, equivalent to $1.2B of an $8B market.
- Forecasted 5% market share in the $150B anti-inflammatory sector, amounting to $7.5B.
- Aiming for a 10% share in IBD treatments, representing $2.3B in a $23B market.
- Total additional market share targeted is $11B.
- The products cater to a growing demand in cellular therapeutics for Lyme disease, chronic inflammation, autoimmune, and other degenerative diseases.